Keyword: Arbutus Biopharma

Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis.

The agreement sets the companies up to work together on five programs targeting rare diseases and another five against cancers.

Former Ariad CEO leads Roivant and Arbutus' new RNA JV, Purdue Pharma names new R&D head, Immunomedics poaches AZ I-O exec as R&D chief.

Genevant has RNA technology from Arbutus, $37.5 million in seed funding from Roivant and plans to take 5 to 10 programs into the clinic by 2020.

Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.

Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.